日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer

植物制剂PHY906联合卡培他滨作为二线疗法治疗晚期胰腺癌患者的首个人体II期临床试验

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-013-2359-7
Saif, Muhammad Wasif; Li, Jia; Lamb, Lynne; Kaley, Kristin; Elligers, Kyle; Jiang, Zaoli; Bussom, Scott; Liu, Shwu-Huey; Cheng, Yung-Chi
胰腺癌
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

利用液相色谱/串联质谱法 (LC/MS/MS) 对接受伊立替康和 PHY906 治疗的患者血浆中的化学物质及其代谢物进行鉴定

期刊:Journal of Chromatography A
影响因子:4
doi:10.1016/j.chroma.2010.07.045
Zhang Wei, Saif Muhammad W, Dutschman Ginger E, Li Xin, Lam Wing, Bussom Scott, Jiang Zaoli, Ye Min, Chu Edward, Cheng Yung-Chi
代谢
发表日期：2010
文献求助 收藏